ASK REDCHAT ANYTHING ABOUT ZYMEWORKS INC.
Zymeworks Inc. (NASDAQ: ZYME)
Listen to this Section
$24.01
-0.1010
(
-0.42% )
230.2K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Zanidatamab (HER2)DetailsGastroesophageal adenocarcinomas, Cancer, CholangiocarcinomaBig Mover™Suspected Mover™Susp. Mover™ |
Phase 3 |
| Zanidatamab + Chemo/trastuzumabDetailsBreast cancer, Cancer, HER2-expressing cancers |
Phase 3 |
| Zanidatamab zovodotin (ZW49)DetailsHER2-expressing cancers, Cancer, Non-small cell lung carcinoma |
Phase 2 |
| Zanidatamab (HER2) + chemotherapy + tislelizumabDetailsCancer, Gastroesophageal adenocarcinomas, Cholangiocarcinoma |
Phase 2 |
| Zanidatamab (HER2) + docetaxelDetailsCancer, Breast cancer |
Phase 1/2 |
| ZW171DetailsCancer, Mesothelin-expressing solid tumors |
Phase 1 |
| ZW191DetailsCancer |
Phase 1 |
| Ziihera® (zanidatamab-hrii)DetailsCancer, Solid tumor/s, Biliary Tract Cancer |
Approved |
| ZW191DetailsCancer, Solid tumor/s |
Phase 1 |
Market Data
|
| Open |
$24.01 |
| Previous Close |
$24.11 |
| Volume |
230.2K |
| Market Cap |
$1.77B |
| Day Range |
$23.79 - $24.45 |
| 52 Week Range |
$11.51 - $29.75 |
| Shares Outstanding |
73.57M |
| Change % |
-0.42% |
| Net Change |
▼ -0.1010 |
| Insider Ownership |
-0.11% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | None |
| IPO Year | 2017 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
4,583,287.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2025-05-19 |
Buy |
49502.00 |
EcoR1 Capital, LLC |
| 2025-01-15 |
Buy |
74125.00 |
EcoR1 Capital, LLC |
| 2025-01-10 |
Buy |
21021.00 |
EcoR1 Capital, LLC |
| 2024-04-02 |
Sale |
-74000.00 |
Gallagher Neil |
| 2024-02-09 |
Sale |
-74000.00 |
Cesano Alessandra |
| 2024-01-08 |
Sale |
-47666.00 |
Galbraith Kenneth |
| 2024-01-08 |
Sale |
-90000.00 |
Smith Jeffrey T L |
| 2024-01-08 |
Sale |
-10500.00 |
Astle Christopher |
| 2024-01-08 |
Sale |
-17166.00 |
Moore Paul Andrew |
| 2023-12-28 |
Buy |
5086521.00 |
EcoR1 Capital, LLC |